Current:Home > StocksALS drug's approval draws cheers from patients, questions from skeptics-InfoLens
ALS drug's approval draws cheers from patients, questions from skeptics
View Date:2024-12-23 18:52:22
The Food and Drug Administration has approved a controversial new drug for the fatal condition known as ALS, or Lou Gehrig's disease.
The decision is being hailed by patients and their advocates, but questioned by some scientists.
Relyvrio, made by Amylyx Pharmaceuticals of Cambridge, Mass., was approved based on a single study of just 137 patients. Results suggested the drug might extend patients' lives by five to six months, or more.
"Six months can be someone attending their daughter's graduation, a wedding, the birth of a child," says Calaneet Balas, president and CEO of the ALS Association. "These are really big, monumental things that many people want to make sure that they're around to see and be a part of."
Balas says approval was the right decision because patients with ALS typically die within two to five years of a diagnosis, and "right now there just aren't a lot of drugs available."
But Dr. David Rind, chief medical officer for the Institute for Clinical and Economic Review, isn't so sure about Relyvrio, which will cost about $158,000 a year.
"I totally understand why people would be trying to figure out a way to get this to patients," he says. "There's just a general concern out there that maybe the trial is wrong."
ALS kills about 6,000 people a year in the U.S. by gradually destroying nerve cells that control voluntary movements, like walking, talking, eating, and even breathing. Relyvrio, a combination of two existing products, is intended to slow down the disease process.
Proponents of the drug say the small trial showed that it works. But FDA scientists and an expert panel that advises the FDA, weren't so sure.
Typically, FDA approval requires two independent studies – each with hundreds of participants – showing effectiveness, or one large study with clearly positive results.
In March, the Peripheral and Central Nervous System Drugs Advisory committee concluded that the Amylyx study did not provide "substantial evidence" that its drug was effective. Then in September, during a rare second meeting to consider a drug, the panel reversed course and voted in favor of approval.
The second vote came after Dr. Billy Dunn, director of the FDA's Office of Neuroscience, encouraged the committee to exercise "flexibility" when considering a drug that might help people facing certain death.
A much larger study of Relyvrio, the Phoenix Trial, is under way. But results are more than a year off.
A negative result from that study would be a major blow to Amylyx and ALS patients.
"If you've got a drug that's extending life by five months," Rind says, "you ought to be able to show that in a larger trial."
In the meantime, he says, perhaps Amylix should charge less for their drug.
Relyvrio (marketed as Albrioza in Canada) is the only product made by Amylyx, a company founded less than a decade ago by Joshua Cohen and Justin Klee, who attended Brown University together.
Klee defends the drug's price, saying it will allow the company to develop even better treatments. "This is not a cure," he says. "We need to keep investing until we cure ALS."
Klee and Cohen have also promised that Amylyx will re-evaluate its drug based on the results of the Phoenix trial.
"If the Phoenix trial is not successful," Klee says, "we will do what's right for patients, which includes taking the drug voluntarily off the market."
But that the decision would require support from the company's investors, and its board of directors.
veryGood! (7965)
Related
- Here's Your First Look at The White Lotus Season 3 With Blackpink’s Lisa and More Stars
- Paula Abdul Sues American Idol EP Nigel Lythgoe for Sexual Assault
- Bacon bits: Wendy's confirms one cent Jr. Bacon Cheeseburger offer has limit
- Bowl game schedule today: Breaking down the four college football bowl games on Dec. 30
- Judge sets date for 9/11 defendants to enter pleas, deepening battle over court’s independence
- SoundHound AI Stock has plunged. But could it be on the upswing next year?
- Brazil expresses concern over Venezuela-Guyana border dispute as naval exercises begin in area
- Buy the Gifts You Really Wanted With 87% Off Deals on Peter Thomas Roth, Tarte, Peace Out & More
- NFL Week 10 winners, losers: Cowboys' season can no longer be saved
- Shopping on New Year’s Day 2024? From Costco to Walmart, see what stores are open and closed
Ranking
- TikToker Campbell “Pookie” Puckett Gives Birth, Welcomes First Baby With Jett Puckett
- Texas standout point guard Rori Harmon out for season with knee injury
- Browns receiver Elijah Moore back home after being hospitalized overnight with concussion
- Court in Canadian province blocks new laws against public use of illegal substances
- Trump has promised to ‘save TikTok’. What happens next is less clear
- Medical marijuana dispensary licenses blocked in Alabama amid dispute over selection process
- Matthew McConaughey shares rare photo of son Livingston: 'We love watching you grow'
- Mexico and Venezuela restart repatriation flights amid pressure to curb soaring migration to U.S.
Recommendation
-
Investigation into Chinese hacking reveals ‘broad and significant’ spying effort, FBI says
-
Shirley Bassey and Ridley Scott are among hundreds awarded in UK’s New Year Honors list
-
Live updates | Tens of thousands of Palestinians stream into Rafah as Israel expands its offensive
-
The Best 2024 Planners for Slaying the New Year That Are So Cute & Useful
-
BITFII Introduce
-
Powerful Pacific swell brings threat of more dangerous surf to California
-
North Dakota lawmaker’s district GOP echoes call on him to resign after slurs to police in DUI stop
-
New Year's resolutions experts say to skip — or how to tweak them for success